Food and herbal nutritional products » Herpes » AiCuris Presents Preclinical and Phase 1 Data of its anti-HSV drug AIC316
AiCuris Presents Preclinical and Phase 1 Data of its anti-HSV drug AIC316
View PDF | Print View
by: Guest
Total views: 440 Word Count: 442
Phase 1 data on AIC316 at the Antivirals Congress in Amsterdam, Netherlands, from 7 th - 9 th of November 2010. AIC316 is a novel anti-HSV drug currently in clinical phase 2 testing.
AiCuris scientist and project leader Dr. Alexander Birkmann will give an overview on the pharmacokinetic-pharmacodynamic relationship of AIC316 by presenting efficacy data from experiments performed in a murine infection model and Phase 1 pharmacokinetic data which demonstrate that the predicted efficacious concentrations of AIC316 will be easily achieved in humans. The oral presentation will be held during Plenary Session 5 on "Antiviral Resistance" scheduled for Monday, November 8, 2010, at 14:40 hrs, NH Grand Hotel Krasnapolsky, Amsterdam.
"The results also clearly confirm that AIC316 has the potential for once daily dosing which we consider as a prerequisite for the intended indication of genital herpes" said Dr. Holger Zimmermann, Chief Scientific Officer of AiCuris. AiCuris' CEO Prof. Helga R However, we know that patients may suffer tremendously, physically and psychologically and that the unmet medical need is still very high. Therefore we are committed to make a real difference with an innovative and resistance-breaking drug against Herpes simplex."
About herpes
Herpes simplex viruses (HSV) are widespread in the human population (seroprevalence up to 100%, depending on geographic area and subpopulation), and are divided into herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2). While HSV-1 predominantly causes oral lesions (cold sores), HSV-2 manifests in the genital region and is mainly being transmitted sexually. However, the past decade has seen an increase in HSV-1 genital infections, which now account for at least half of first episodes of genital herpes in some countries. Both labial and genital herpes are generally self-limiting and can recur frequently. HSV infections have also been associated with a three-fold increase in the risk of sexually acquired HIV. In immune compromised individuals large and painful ulcerations may result, and newborns infected with HSV are at risk of developing herpes encephalitis. Most of the current herpes drugs inhibit a specific viral enzyme, the DNA polymerase. They share the same mode of action and are therefore very similar in their efficacy. Also, cross-resistance can occur.
About AiCuris - www.aicuris.com
AiCuris GmbH & Co KG is a privately held company located in Wuppertal, Germany. It is devoted to research and clinical development of novel, resistance-breaking drugs which are well-differentiated from the standard of care for the treatment of HCMV, Herpes, Hepatitis B, HIV and Hepatitis C as well as resistant Gram positive and Gram negative bacterial infections in hospitals. Furthermore, the portfolio comprises two immune modulators.
Contact:
AiCuris GmbH & Co. KG
Sandra Wildhagen
Friedrich-Ebert-Str. 475/Building 302
42117 Wuppertal
Additional information:
Evaluation of a Novel, Anti Herpes Simplex Virus Compound
Drugswatcher. Online Pharmacy. Canadian Pharmacies, Canada Drugs.
Building Anti Herpes Anti-Viral Immunity As Part of Natural
Find the Rigth Anti Herpes Product
Leadmedic. Online Pharmacy. Generic Viagra, Cialis.
Herpes Photos and Pictures
Potentiating Effect of Mizoribine on the Anti Herpes Virus
Dashboard Compiere Wiki
Blood Identification of anti herpes simplex virus antibody
http://www.b3cnewswire.com/201...
Related "Herpes":
- Love, H Style Is the Ultimate Herpes and HPV Social Networking Community
Love, H Style is helping people worldwide increa ... - Allergan Receives FDA Approval for OZURDEX(R) as Treatment Option for Non ...
IRVINE, Calif., Sep 24, 2010 (BUSINESS WIRE) -- ... - Why British oysters are off the menu
Back in the 1980s, I once had a peripatetic lunc ... - Child's horrific injuries described, prosecutor tells Coe: 'You are guilty'
Lucas Coe, left, charged in the sexual assault o ... - Scientists working on chronic stress vax
Stanford scientists may be on the verge of a vac ...
Rating: Not yet rated (votes: 0)
